3 results
This amendment (extension to CRT-D subjects) aims to assess the economic effects of HM technology vs. classical follow-up of CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on…
To measure APC resistance and SHBG levels as indicators of the risk of venous thrombosis during use of the new developed combined oral contraceptive containing dienogest/estradiolvalerate (Qlaira®) compared with a combined oral contraceptive…
To establish the MaximumTolerated Dose, Dose Limiting Toxicities, and the safety profile of BMS-833923 administered in combination with cisplatin and capecitabine as first-line therapy. To describe preliminary evidence of tumor response as measured…